A non-small cell lung carcinoma patient responded to crizotinib therapy after alectinib-induced interstitial lung disease / 浙江大学学报·医学版
Journal of Zhejiang University. Medical sciences
; (6): 583-587, 2023.
Article
em En
| WPRIM
| ID: wpr-1009920
Biblioteca responsável:
WPRO
ABSTRACT
A 54-year-old, non-smoking woman was diagnosed as stage ⅣB adenocarcinoma with widespread bone metastasis (cT4N2M1c) in the First Affiliated Hospital, Zhejiang University School of Medicine. Immunohistochemistry result showed the presence of anaplastic lymphoma kinase (ALK) gene rearrangement; next-generation sequencing (NGS) indicated EML4-ALK fusion (E6:A20) with concurrent CCDC148-ALK (C1:A20), PKDCC-ALK (Pintergenic:A20)and VIT-ALK (V15:A20) fusions. After 32 weeks of alectinib treatment, the patient complained cough and exertional chest distress but had no sign of infection. Computed tomography (CT) showed bilateral diffuse ground glass opacities, suggesting a diagnosis of alectinib-related interstitial lung disease (ILD). Following corticosteroid treatment and discontinuation of alectinib, clinical presentations and CT scan gradually improved, but the primary lung lesions enlarged during the regular follow-up. The administration of crizotinib was then initiated and the disease was stable for 25 months without recurrence of primary lung lesions and ILD.
Palavras-chave
Texto completo:
1
Base de dados:
WPRIM
Assunto principal:
Doenças Pulmonares Intersticiais
/
Carcinoma Pulmonar de Células não Pequenas
/
Crizotinibe
/
Quinase do Linfoma Anaplásico
/
Neoplasias Pulmonares
Limite:
Female
/
Humans
Idioma:
En
Revista:
Journal of Zhejiang University. Medical sciences
Ano de publicação:
2023
Tipo de documento:
Article